Glaukos Corporation (GKOS)
| Market Cap | 7.84B +45.2% |
| Revenue (ttm) | 551.35M +36.3% |
| Net Income | -189.33M |
| EPS | -3.29 |
| Shares Out | 58.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 454,477 |
| Open | 135.12 |
| Previous Close | 134.15 |
| Day's Range | 130.04 - 135.26 |
| 52-Week Range | 73.16 - 146.75 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 133.18 (-0.25%) |
| Earnings Date | Apr 29, 2026 |
About GKOS
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and ... [Read more]
Financial Performance
In 2025, Glaukos's revenue was $507.44 million, an increase of 32.33% compared to the previous year's $383.48 million. Losses were -$187.69 million, 28.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for GKOS stock is "Strong Buy." The 12-month stock price target is $133.18, which is a decrease of -0.25% from the latest price.
News
Glaukos price target raised to $153 from $134 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Glaukos (GKOS) to $153 from $134 and keeps a Buy rating on the shares. Glaukos reported strong Q1 results with revenue and
Glaukos price target raised to $170 from $160 at Stifel
Stifel analyst Thomas Stephan raised the firm’s price target on Glaukos (GKOS) to $170 from $160 and keeps a Buy rating on the shares.
Glaukos price target raised to $140 from $120 at JPMorgan
JPMorgan raised the firm’s price target on Glaukos (GKOS) to $140 from $120 and keeps an Overweight rating on the shares.
Glaukos price target raised to $136 from $127 at Needham
Needham raised the firm’s price target on Glaukos (GKOS) to $136 from $127 and keeps a Buy rating on the shares.
Glaukos price target raised to $141 from $131 at BTIG
BTIG raised the firm’s price target on Glaukos (GKOS) to $141 from $131 and keeps a Buy rating on the shares. The company’s Glaucoma and iDose revenue exceeded the firm’s
Glaukos price target raised to $140 from $135 at Citi
Citi raised the firm’s price target on Glaukos (GKOS) to $140 from $135 and keeps a Buy rating on the shares.
Glaukos reports Q1 EPS (18c), consensus (28c)
Reports Q1 revenue $150.6M, consensus $137.0M. “Our record first quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positi...
Glaukos sees FY26 revenue $620M-$635M, consensus $614.4M
16:27 EDT Glaukos (GKOS) sees FY26 revenue $620M-$635M, consensus $614.4M
Glaukos Earnings Call Transcript: Q1 2026
Record Q1 sales growth of 41% year-over-year led to raised full-year guidance, driven by strong adoption of iDose TR and the Epioxa launch. Investments in commercial expansion, payer coverage, and clinical pipeline support continued momentum and operating leverage.
Glaukos Announces First Quarter 2026 Financial Results
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos Announces the Release of its 2025 Sustainability Report
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos receives permanent J-code for Epioxa
Glaukos (GKOS) Corporation announced the U.S. Centers for Medicare and Medicaid Services has assigned a unique, permanent Healthcare Common Procedure Coding System J-code for Epioxa HD / Epioxa for th...
Glaukos Receives Permanent J-code for Epioxa™
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos price target raised to $135 from $125 at Citi
Citi raised the firm’s price target on Glaukos (GKOS) to $135 from $125 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology group
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos announces commercial availability of Epioxa HD/Epioxa
Glaukos (GKOS) announced the commercial availability of Epioxa HD/Epioxa, an advancement in corneal cross-linking for the treatment of keratoconus. Epioxa is now commercially available for ordering di...
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos management to meet with Piper Sandler
Meeting to be held in Boston on March 18 hosted by Piper Sandler.
Glaukos price target raised to $127 from $125 at Needham
Needham analyst David Saxon raised the firm’s price target on Glaukos (GKOS) to $127 from $125 and keeps a Buy rating on the shares after its Q4 revenue came in-line
Glaukos price target raised to $135 from $122 at Wells Fargo
Wells Fargo raised the firm’s price target on Glaukos (GKOS) to $135 from $122 and keeps an Overweight rating on the shares. The firm notes the company reported Q4 sales
Glaukos Earnings Call Transcript: Q4 2025
Record 2025 sales grew 32% year-over-year, driven by iDose TR and strong U.S. glaucoma performance. 2026 guidance targets $600M–$620M in net sales, with continued growth expected from iDose TR and the Epioxa launch, despite anticipated volatility during the Photrexa transition.
Glaukos reports Q4 adjusted EPS (28c), consensus (30c)
Reports Q4 revenue $143.1M, consensus $137.02M. “Our record fourth quarter results cap off a highly successful year of global execution across our key commercial and development initiatives, leaving u...
Glaukos sees FY26 revenue $600M-$620M, consensus $613.35M
16:07 EST Glaukos (GKOS) sees FY26 revenue $600M-$620M, consensus $613.35M
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...